RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:79433

Oculocutaneous albinism type 3

low confidenceDisorder

Also known as: OCA3 · Red oculocutaneous albinism · Rufous oculocutaneous albinism · Xanthous oculocutaneous albinism

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

4,296

Trials

0

Interventional, condition-specific

Researchers

773

Distinct authors in sample

Gene link

TYRP1

Definitive

Readiness

4/6

Stages with a signal

Clinical definition (Orphanet)

A form of oculocutaneous albinism (OCA) characterized by rufous or brown albinism and occurring mainly in the African population.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (5)

TYRP1 oculocutaneous albinism · oculocutaneous albinism caused by mutation in TYRP1 · oculocutaneous albinism type 3 · rufous oculocutaneous albinism · xanthous oculocutaneous albinism

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedPresent

    Definitive — TYRP1

  2. LiteraturePresent

    4,296 matched papers (2,744 in last 10 years) Source

  3. Phenotype characterisedPresent

    18 HPO annotations (e.g. Strabismus; Albinism; Nystagmus) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPartial

    None under the specific name; 6 for broader category oculocutaneous albinism

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (TYRP1).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

18

Associated phenotypes · MONDO:0008747

  • Strabismus
  • Albinism
  • Nystagmus
  • Red hair
  • Partial albinism

Showing 5 of 18 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

4,296

4,296 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

4,296 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

2,744 in the last 10 years · low confidence

Phrase hits: 122 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

773

Distinct author names in 122 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Dolinska MB5 papers · 2026

    National Eye Institute, National Institutes of Health, Bethesda, Maryland.

    Papers in Europe PMC
  2. 02
    Liu Y5 papers · 2025

    Department of Genetics, Jiangxi Maternal and Child Health Hospital, 330006, Nanchang, China.

    Papers in Europe PMC
  3. 03
    Sergeev YV5 papers · 2026

    National Eye Institute, National Institutes of Health, Bethesda, Maryland.

    Papers in Europe PMC
  4. 04
    Boissy RE4 papers · 2013
    Papers in Europe PMC
  5. 05
    Manga P4 papers · 2013

    Department of Dermatology, University of Cincinnati, PO Box 670592, Cincinnati, OH 45267-0592, USA.

    Papers in Europe PMC
  6. 06
    Brooks BP3 papers · 2022

    National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA. brooksb@mail.nih.gov

    Papers in Europe PMC
  7. 07
    Ferreira PA3 papers · 2011

    Departments of Ophthalmology, Duke University Medical Center, Erwin Road, Durham, NC 27710, USA. ferre044@mc.duke.edu

    Papers in Europe PMC
  8. 08
    Hearing VJ3 papers · 2014
    Papers in Europe PMC
  9. 09
    Jenkins T3 papers · 2001
    Papers in Europe PMC
  10. 10
    Kromberg JG3 papers · 1997

    MRC Ecogenetics Unit, Department of Human Genetics, School of Pathology, SA Institute for Medical Research, Johannesburg, South Africa.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 6 trials are registered for oculocutaneous albinism, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

low confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

6 interventional trials matched oculocutaneous albinism, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: oculocutaneous albinism

6

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Oculocutaneous albinism type 3 — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Oculocutaneous albinism type 3" OR "Red oculocutaneous albinism" OR "Rufous oculocutaneous albinism" OR "Xanthous oculocutaneous albinism" OR "TYRP1 oculocutaneous albinism" OR "oculocutaneous albinism caused by mutation in TYRP1") OR (MESH:"[OBSOLETE] Oculocutaneous albinism type 3") OR ("TYRP1" OR "TYRP1 syndrome" OR "TYRP1-related")

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: [OBSOLETE] Oculocutaneous albinism type 3

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Oculocutaneous albinism type 3" OR "Red oculocutaneous albinism" OR "Rufous oculocutaneous albinism" OR "Xanthous oculocutaneous albinism" OR "TYRP1 oculocutaneous albinism" OR "oculocutaneous albinism caused by mutation in TYRP1" OR "[OBSOLETE] Oculocutaneous albinism type 3"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"oculocutaneous albinism"

Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: OCA3

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (4296) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-27T02:24:46.872Z